American doctors have now discovered the injections put users at 'significantly higher' risk compared to three other common diabetes drugs.

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

Dr. George Carroll runs BeSlimMD, a private weight loss clinic in Maitland. He has been helping patients lose weight for more than 40 years, but says when so called GLP-1 drugs made from semaglutide ...

Paris Fashion Week was visited by Whoopi Goldberg recently, with the View host and EGOT winner attending a fashion ...

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...

Weight loss is a common goal for many, and while diet and exercise remain essential, some turn to medications like Mounjaro ...

Developed initially to manage diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in popularity ...

Research shows that people who take these weight-loss medications may have a lower risk of dementia and numerous other health ...

Researchers took drugs currently used to treat type 2 diabetes and obesity and looked into how they affect 175 conditions.

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

GLP-1 weight loss drugs - such as Wegovy and Mounjaro - may reduce risk of conditions including Alzheimer’s disease and ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.